Clinical Trial Protocol: Alzheimer's Dementia Underlying Encephalopathy
About this study
The goal of this clinical trial is to determine if utilizing the Quest AD-Detect blood test, while patient's are hospitalized for a cognitive diagnosis (such as delirium or encephalopathy), will result in an earlier diagnosis of underlying Alzheimer's disease. * Will this blood test have the ability to distinguish between Alzheimer's disease and other causes of cognitive impairment in the inpatient setting? * Neurology Clinic will complete a 6-month post-hospitalization follow up with patients who have had the Quest AD-Detect Alzheimer's Disease blood test completed while they were inpatient to discuss the risk assessment portfolio
- Condition
- Alzheimer Dementia, Alzheimer Disease, Delirium Confusional State, Encephalopathy, Cognitive Abnormality
- Tested
- Quest AD-Detect blood test
- Sponsor
- Covenant Health, US
Who can join
- Age
- 60 to 90 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Minimum age: 60 years
- Maximum age: 90 years
- Study condition: Alzheimer Dementia, Alzheimer Disease, Delirium Confusional State, Encephalopathy, Cognitive Abnormality
- Ages 60 to 90 years old
- No prior diagnosis of dementia
- Currently hospitalized with cognitive diagnosis, including but no limited to; delirium, encephalopathy, etc. thought to be secondary to a toxic/metabolic state
Exclusion 2
- Age under 60 years
- Prior diagnosis of dementing illness or other organic etiology to cognitive impairment
Where
6 sites, 6 recruiting
Cumberland Medical Center
Crossville, Tennessee, United States
Roane Medical Center
Harriman, Tennessee, United States
Fort Sanders Regional Medical Center
Knoxville, Tennessee, United States
Fort Loudon Medical Center
Lenoir City, Tennessee, United States
Methodist Medical Center
Oak Ridge, Tennessee, United States
LeConte Medical Center
Sevierville, Tennessee, United States
Contact
-
Clinical Research Nurse Coordinator
865-331-1337 aholt10@covhlth.com
Potential match only. Final eligibility is determined by the study team.